⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11877105 | 0.84 | — | — | |
| SCHEMBL171318 | 0.82 | — | — | |
| SCHEMBL6897108 | 0.82 | — | — | |
| SCHEMBL222921 | 0.82 | — | — | |
| SCHEMBL282622 | 0.82 | — | — | |
| SCHEMBL28363666 | 0.81 | — | — | |
| SCHEMBL28363664 | 0.81 | — | — | |
| SCHEMBL19122502 | 0.81 | — | — | |
| SCHEMBL10617334 | 0.80 | LMNA (0.74) | — | |
| Hydrochloric Acid SCHEMBL29769105 | 0.79 | LMNA (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069984-A | Morpholinyl hindered amine compound is in the purposes being selectively removed in hydrogen sulfide | 巴斯夫欧洲公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| CN-101155781-B | Pyridine-3-carboxamide derivatives as cb1 inverse agonists | HOFFMANN LA ROCHE | 2012-11-07 | — | — | CN | disclosed |
| US-7851439-B2 | EFTU inhibitors or aminothiazoles and their uses | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2010-10-21 | — | — | US | disclosed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008148754-A2 | MACROCYCLES AND THEIR USES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| CN-101155781-A | Pyridine-3-carboxamide derivatives as cb1 inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| EP-1868999-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |